[The use of bevacizumab in refractory peritoneal dissemination of gastric cancer with malignant ascites-two case reports].
Vascular endothelial growth factor (VEGF) plays an important role in proliferation of cancer cells, angiogenesis and vascular permeability in peritoneal dissemination. In addition, the release of VEGF by tumor cells has been identified as a main factor promoting the intraperitoneal secretion of fluid. Accordingly, recent evidence suggests that targeting VEGF may have the potential to suspend the ascites production resulting from peritoneal metastasis. We previously reported the effects of bevacizumab (BEV) on the growth inhabitation of peritoneal nodules and the reduction of ascites in peritoneal metastatic models. Here we present two cases of women (62 and 42 years old) with refractory peritoneal dissemination of scirrhous gastric cancer and server symptomatic ascites. They required frequent paracenteses for ascites which was resistant to systemic and intraperitoneal chemotherapy of S-1 and taxane. We treated them with intravenous BEV (5-10 mg/kg) with dramatic improvement in their ascites. BEV may have a role in the management of malignant ascites in the patient with refractory gastric cancer which should be confirmed in a larger series of well selected patients.
Dept. of Gastroenterological Surgery, Kanazawa University.
Jun
J
Kinoshita
Sachio
S
Fushida
Isamu
I
Makino
Keishi
K
Nakamura
Katsunobu
K
Oyama
Hisatoshi
H
Nakagawara
Hideto
H
Fujita
Hidehiro
H
Tajima
Hiroyuki
H
Takamura
Itasu
I
Ninomiya
Hirohisa
H
Kitagawa
Takashi
T
Tani
Masatoshi
M
Miyamoto
Takashi
T
Fujimura
Tetsuo
T
Ota
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001201:Ascites / Q000209:etiology*; D000068258:Bevacizumab; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000150:complications / Q000188:drug therapy*; D013274:Stomach Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab